Oral Delivery of Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Emerging evidences indicate that diminished activity of the vasoprotective axis of the renin–angiotensin system, constituting angiotensin-converting enzyme 2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to the pathogenesis of pulmonary hypertension (PH). However, long-term repetitive delivery of ACE2 or Ang-(1-7) would require enhanced protein stability and ease of administration to improve patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect against gastric enzymatic degradation and facilitates long-term storage at room temperature. Besides, fusion to a transmucosal carrier helps effective systemic absorption from the intestine on oral delivery. We hypothesized that bioencapsulating ACE2 or Ang-(1-7) fused to the cholera nontoxin B subunit would enable development of an oral delivery system that is effective in treating PH. PH was induced in male Sprague Dawley rats by monocrotaline administration. Subset of animals was simultaneously treated with bioencapsulaed ACE2 or Ang-(1-7) (prevention protocol). In a separate set of experiments, drug treatment was initiated after 2 weeks of PH induction (reversal protocol). Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) prevented the development of monocrotaline-induced PH and improved associated cardiopulmonary pathophysiology. Furthermore, in the reversal protocol, oral ACE2 or Ang-(1-7) treatment significantly arrested disease progression, along with improvement in right heart function, and decrease in pulmonary vessel wall thickness. In addition, a combination therapy with ACE2 and Ang-(1-7) augmented the beneficial effects against monocrotaline-induced lung injury. Our study provides proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary disease therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676 · cited 8×
“We hypothesized that bioencapsulating ACE2 or Ang-(1-7) fused to the cholera nontoxin B subunit would enable development of an oral delivery system that is effective in treating PH.”
BackgroundMethodInfluentialInteraction of cholera toxin and membrane GM1 ganglioside of small intestine
Holmgren, J., Lönnroth, I., Månsson, J., & Svennerholm, L. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.7.2520 · Cited by 376
Dysregulated Renin–Angiotensin–Aldosterone System Contributes to Pulmonary Arterial Hypertension
de Man, F. S., Tu, L., Handoko, M. L., Rain, S., Ruiter, G., François, C., Schalij, I., Dorfmüller, P., Simonneau, G., Fadel, E., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0411oc · Cited by 346
Cited by
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
Self-citationChloroplast genomes: diversity, evolution, and applications in genetic engineering
Daniell, H., Lin, C.-S., Yu, M., & Chang, W.-J. (2016) · Genome Biology · doi:10.1186/s13059-016-1004-2 · Cited by 1,720
Self-citationThe ACE2/angiotensin-(1-7)/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)
Santos, R. A. S., Sampaio, W. O., Alzamora, A. C., Motta-Santos, D., Alenina, N., Bader, M., & Campagnole-Santos, M. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00023.2016 · Cited by 1,144
Endothelial dysfunction and vascular disease - a 30th anniversary update
Vanhoutte, P. M., Shimokawa, H., Feletou, M., & Tang, E. H. C. (2017) · Acta Physiologica · doi:10.1111/apha.12646 · Cited by 937
“…radicals leading to reduced activity of eNOS (resulting from a tighter coupling to caveolin-1) and a diminished bioavailability of NO (Fresquet et al. 2006, Jerkic et al. 2011, d’Uscio 2011, Shenoy et al. 2013, 2014, Kuriyama et al. 2014, NozikGrayck et al. 2014, Teichert-Kuliszewska et al. 2015).”
BackgroundRole of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure
Patel, V. B., Zhong, J.-C., Grant, M. B., & Oudit, G. Y. (2016) · Circulation Research · doi:10.1161/circresaha.116.307708 · Cited by 833
Metadata
- Authors
- Shenoy, V., Kwon, K.-C., Rathinasabapathy, A., Lin, S., Jin, G., Song, C., Shil, P., Nair, A., Qi, Y., Li, Q., Francis, J., Katovich, M. J., Daniell, H., & Raizada, M. K.
- Venue
- Hypertension
- Published
- 2014-12
- Volume
- 64
- Issue
- 6
- Pages
- 1248-1259
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2104188024
- Cited by
- 141
- References
- 3
- FWCI
- 8.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Delivery of Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension. https://app.cochat.ai/papers/10.1161/hypertensionaha.114.03871
- The paper
- Shenoy, V., Kwon, K.-C., Rathinasabapathy, A., Lin, S., Jin, G., Song, C., Shil, P., Nair, A., Qi, Y., Li, Q., Francis, J., Katovich, M. J., Daniell, H., & Raizada, M. K. (2014). Oral Delivery of Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7) Bioencapsulated in Plant Cells Attenuates Pulmonary Hypertension. Hypertension. https://doi.org/10.1161/hypertensionaha.114.03871
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.